EMJ GOLD

Filter Advertise With Us

Exterior of Gilead office building

Gilead reports strong Q2 driven by HIV portfolio

Total revenue increased 10% year-on-year to $7.8bn.

Exterior of Gilead office building

Gilead reports strong Q2 driven by HIV portfolio

Total revenue increased 10% year-on-year to $7.8bn.

BMS office building

12 years after Pfizer, AstraZeneca reaches for BMS

The deal would rank among the largest in pharmaceutical history.

A hospital room with a patient resting in a bed while a healthcare worker and another visitor sit nearby. In the foreground, a bright yellow medical transport bag sits on a table, with monitoring equipment and clinical furnishings visible around the room.

World-first trial delivers personalised lung cancer vaccine

The first patient has received a personalised lung cancer vaccine in a world-first clinical trial for advanced non-small cell lung cancer.

Sanofi sign

Sanofi lifts 2026 outlook as dupilumab tops €5bn

Sanofi raises its full-year 2026 guidance following strong Q2 results, with dupilumab surpassing €5bn in quarterly sales for the first time.

Month in pharma news, explained

Month in pharma news, explained – July 2026

From China’s biotech licensing boom to the UK’s first GLP-1 weight-loss pill, explore the biggest pharma and life sciences stories from July.

Lettuce

Cyclosporiasis outbreak drives fresh produce concerns

A food poisoning outbreak linked to lettuce is driving concerns among consumers.

Rising bar chart

AstraZeneca up 6% in Q2 as oncology drives growth

AstraZeneca maintained revenue growth in the second quarter of 2026 as demand for its oncology medicines grew.

AstraZeneca's HSCT-TMA drug misses main goal in latest trial

AstraZeneca's HSCT-TMA drug misses main endpoint

A phase 3 trial of ravulizumab fell short in adult HSCT-TMA patients, while paediatric results held more promise.

Loading posts...

1 2 3 … 57 Next »